Annexon, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Annexon, Inc. on January 19, 2022. The report discloses corporate governance changes, specifically the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
On January 19, 2022, the Board of Directors appointed Bettina M. Cockroft, M.D., as a new director, effective immediately. Dr. Cockroft serves as a Class III director with a term expiring at the 2023 annual meeting of stockholders.
Compensation and Governance Details
- Annual Retainer: $35,000 for service on the Board.
- Initial Equity Grant: Automatic grant of a stock option to purchase 20,000 shares of Common Stock under the 2020 Incentive Award Plan.
- Annual Equity Grant: Automatic grant of a stock option to purchase 10,000 shares of Common Stock on the date of each annual stockholder meeting.
- Agreements: Dr. Cockroft will enter into the Company's standard indemnification and advancement agreement for directors and executive officers.
Outlook and Risks
The filing does not contain management commentary on financial outlook, risks, contingencies, or unusual items. It references a press release dated January 20, 2022, regarding the appointment, which is furnished as an exhibit but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the terms of the 2020 Incentive Award Plan referenced for the stock option grants.
- Review the Company's non-employee director compensation program filed as Exhibit 10.12 to the Form S-1 (July 20, 2020).
- Confirm the standard indemnification and advancement agreement terms filed as Exhibit 10.12 to the Form S-1 (July 2, 2020).
- Check the press release (Exhibit 99.1) for additional context on Dr. Cockroft's qualifications and the Board's rationale for the appointment.